RecruitingNCT05382572
Pulmonary Fibrosis Foundation Community Registry
Sponsor
Pulmonary Fibrosis Foundation
Enrollment
10,000 participants
Start Date
Jul 11, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form online
- Male or female, aged 18 or older
- Affected by PF as a member of at least one of the following cohorts:
- An individual diagnosed with PF or ILD, including those who are post lung transplant, or
- An individual who has cared (currently or in the past) for an individual with PF or ILD, and / or
- A family member (defined as parent, full or half-sibling, or child) of an individual with PF or ILD.
- Has internet access and a valid email address.
Exclusion Criteria10
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Primary residence or place of care is outside of the US.
- Inability or unwillingness of a participant to provide informed consent or comply with study protocol.
- Any condition or circumstance not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
- Patients who were diagnosed with any of the below lung diseases. Similarly caregivers and family members associated with these diseases would be excluded.
- Sarcoid
- Lymphangioleiomyomatosis (LAM)
- Pulmonary alveolar proteinosis (PAP)
- Cystic fibrosis (CF)
- Amyloidosis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05382572
Related Trials
dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound
NCT062356451 location
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622371 locations
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT0703652347 locations
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
NCT062415603 locations
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
NCT032977751 location